MediciNova Inc. (MNOV) is having a rough Monday. The biotech reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus, and the market's verdict was swift.

The exploratory study did produce improvements in cardiovascular lipid markers, along with positive trends in liver fat reduction and body weight loss. But trends, as any biotech investor knows, are not the same as statistical significance.

The Trial Design and What Actually Worked

The MN-001-NATG-202 study evaluated the efficacy, safety, and tolerability of MN-001 over a 24-week treatment period in 40 patients.

At Week 4, participants receiving MN-001 experienced a statistically significant mean decrease in serum triglycerides of 54.7 mg/dL (26.05%), compared to a 23.8 mg/dL (11.54%) reduction in the placebo arm (p=0.015).

By Week 24, serum triglycerides in the MN-001 cohort dropped by 45.8 mg/dL (21.78%) versus 14.4 mg/dL (6.97%) for placebo, representing a numerical improvement of 31.4 mg/dL.

At Week 24, MN-001 generated a statistically significant increase in mean HDL cholesterol of 3.3 mg/dL (8.39%), whereas placebo levels fell by 2.4 mg/dL (6.23%) (p=0.0048).

HDL particle concentration also rose significantly by 3.62 µmol/L (11.80%) in the MN-001 group, compared to a 0.9 µmol/L (3.00%) decrease in placebo (p=0.018).

So far, so good on the lipid front. Then came the liver fat data.

Regarding liver fat, controlled attenuation parameter scores measured by FibroScan dropped by 14.1 dB/m (4.24%) with MN-001 versus 4.3 dB/m (1.27%) with placebo. However, the difference was not statistically significant (p=0.2438).

Additionally, the treatment group lost a mean of 4.91 pounds (2.28%) compared to 0.55 pounds (0.25%) in the placebo arm.

Safety Profile and What Comes Next

MN-001 showed a favorable safety and tolerability profile throughout the study. Treatment-related adverse events remained mild to moderate, with zero drug-related serious adverse events reported.

These clinical findings align with earlier preclinical in vitro mechanism of action studies and results from the prior MN-001-NATG-201 trial.

Following this 40-patient proof-of-concept study, MediciNova plans to complete detailed data analyses to assess the next stage of clinical development.

MNOV Price Action: MediciNova shares were down 26.36% at $2.36 at the time of publication on Monday, according to market data.